Bayer Schering supports China haemophilia centres
This article was originally published in Scrip
Executive Summary
Bayer Scheringhas pledged a total of €1.5 million over the next five years to fund the development of haemophilia treatment centres in China. The firm has linked with the Chinese Society of Hematology to provide equipment, supplies and educational materials to, and support patient and nursing programmes at, the six existing centres in the country, where an estimated 70,000 to 100,000 people suffer from the disorder. The aim is to develop the network to provide a full range of services in support of improved diagnosis and treatment. Bayer Schering markets Kogenate, currently the only recombinant Factor VIII product approved in China.